Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Oncternal Therapeutics, Inc. Common Stock (ONCT)

Pharmaceutical Preparations

https://www.oncternal.com

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

12230 EL CAMINO REAL, SUITE 230
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/03/2004

Market Cap

10,388,372

Shares Outstanding

2,960,000

Weighted SO

2,959,739

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

NLTX --.--%

CTMX --.--%

ASMB --.--%

TIL --.--%

NUVB --.--%

TARA --.--%

VCNX --.--%

MNPR --.--%

Beta

1.3560

Last Div

0.0000

Range

3.2528-13.2

Chg

-0.2900

Avg Vol

7070

Mkt Cap

10388372

Exch

NASDAQ

Country

US

Phone

858 434 1113

DCF Diff

3.1949

DCF

0.2851

Div Yield

0.0000

P/S

5.6275

EV Multiple

-0.1126

P/FV

0.6595

Div Yield %

0.0000

P/E

-0.2888

PEG

-0.0155

Payout

0.0000

Current Ratio

2.8873

Quick Ratio

2.8873

Cash Ratio

0.7923

DSO

111.3191

DIO

0.0000

Op Cycle

111.3191

DPO

54.2483

CCC

57.0708

Gross Margin

-5.9361

Op Margin

-20.4052

Pretax Margin

-19.4870

Net Margin

-19.4870

Eff Tax Rate

0.5140

ROA

-1.5077

ROE

1.2003

ROCE

-2.3834

NI/EBT

1.0000

EBT/EBIT

0.9550

EBIT/Rev

-20.4052

Debt Ratio

0.0078

D/E

0.0117

LT Debt/Cap

0.0000

Total Debt/Cap

0.0116

Int Coverage

-4708.5000

CF/Debt

-136.1730

Equity Multi

1.5145

Rec Turnover

3.2789

Pay Turnover

6.7283

Inv Turnover

0.0000

FA Turnover

9.7158

Asset Turnover

0.0774

OCF/Share

-8.5108

FCF/Share

-8.5108

Cash/Share

7.2395

OCF/Sales

-13.6468

FCF/OCF

1.0000

CF Coverage

-136.1730

ST Coverage

-136.1730

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.6595

P/B

0.6595

P/S

5.6275

P/E

-0.2888

P/FCF

-0.4124

P/OCF

-0.4124

P/CF

-0.4124

PEG

-0.0155

P/S

5.6275

EV Multiple

-0.1126

P/FV

0.6595

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 26, 12:20 Crude Oil Rises Over 3%; US Home Prices Increase In October Benzinga Dec 26, 12:20 Crude Oil Rises Over 3%; US Home Prices Increase In October GlobeNewswire Inc. Dec 26, 09:00 Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Revenue Product Segmentation